Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients
March 15, 2023 11:55 ET
|
Trethera Corporation
LOS ANGELES, March 15, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
January 24, 2023 12:12 ET
|
Trethera Corporation
LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
JAPAN HOUSE Los Angeles Presents “Designing With Disaster: Stories From Seven Regenerative Cities”
January 05, 2023 09:00 ET
|
JAPAN HOUSE Los Angeles
LOS ANGELES, Jan. 05, 2023 (GLOBE NEWSWIRE) -- JAPAN HOUSE Los Angeles, a Japanese cultural destination in the heart of Hollywood, announces its upcoming exhibition “Designing with Disaster: Stories...
NewHydrogen reports progress in its quest to lower the cost of producing green hydrogen
December 20, 2022 03:30 ET
|
NewHydrogen, Inc.
NewHydrogen CEO highlights the company’s milestones, and outlines next steps SANTA CLARITA, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC: NEWH), a developer of a breakthrough...
NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
November 08, 2022 10:00 ET
|
NeuroSigma, Inc.
Trials recruiting subjects at UCLA and Seattle Children’s Hospital in the United States, and at King’s College London and the University of Southampton in the United Kingdom Trials sponsored by the...
Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program
October 19, 2022 12:17 ET
|
Trethera Corporation
LOS ANGELES, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting
October 04, 2022 12:23 ET
|
Trethera Corporation
LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Sprouts Farmers Market Aligns with Arizona State University, University of California, Los Angeles, University of Southern California, and University of Texas to Empower Women’s Sports and Health
September 13, 2022 12:00 ET
|
SFM, LLC d/b/a Sprouts Farmers Market
PHOENIX, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sprouts Farmers Market today announced a complement to its long-term commitment and investment to women’s athletics through individual sponsorship...
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models
September 07, 2022 12:37 ET
|
Trethera Corporation
LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Revolutionary Aneutronic Fusion Energy Generator Being Built By Kronos Fusion Energy With Carl Weggel Leading Its Design
August 17, 2022 08:00 ET
|
Kronos Fusion Energy
ARLINGTON, Va., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Carl Weggel—a 50-year persistent advocate of the compact, ultra-high-field tokamak—is on a mission to commercialize fusion energy through Kronos's...